topotecan has been researched along with Cancer of Cervix in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.64) | 18.2507 |
| 2000's | 26 (42.62) | 29.6817 |
| 2010's | 30 (49.18) | 24.3611 |
| 2020's | 4 (6.56) | 2.80 |
| Authors | Studies |
|---|---|
| Chopra, M; Kaur, S; Rajoria, P | 1 |
| Bhosale, P; Chisholm, GB; Flores-Legarreta, A; Frumovitz, M; Gonzales, NR; Hillman, RT; Jhingran, A; Ramalingam, P; Salvo, G | 1 |
| Arens, R; de Graaf, JF; Melief, CJM; Pardieck, IN; van der Burg, SH; van der Maaden, K; van der Sluis, TC; van Duikeren, S; van Haften, FJ; Vleeshouwers, W | 1 |
| Chase, D; Gil, K; Guntupalli, SR; Huang, HQ; Huh, WK; Landrum, LM; Leitao, M; Monk, BJ; Oaknin, A; Penson, RT; Pulaski, HL; Ramondetta, LM; Richardson, D; Robison, K; Salani, R; Sill, MW; Tewari, KS; Wenzel, LB | 1 |
| Guerra, I; McCormack, M; Munk, VC; Nogueira-Rodrigues, A; Rosen, VM; Sasse, A; Shang, A | 1 |
| Chopra, M; Wasim, L | 1 |
| Choi, YS; Jo, DY; Kim, JM; Ko, YB; Lee, HJ; Ryu, H; Song, IC; Yun, HJ | 1 |
| Ko, YB; Lee, HJ; Moon, JY; Song, IC | 1 |
| Alvarez Secord, A; Case, AS; Cohn, DE; Dehdashti, F; Eisenhauer, EL; Gao, F; Lippmann, LT; Massad, LS; Mutch, DG; Powell, MA; Rader, JS; Thaker, PH; Valea, FA; Wright, JD; Zighelboim, I | 1 |
| Huang, H; Landrum, LM; Leitao, MM; Long, HJ; Michael, HE; Monk, BJ; Oaknin, A; Penson, RT; Ramondetta, LM; Reid, TJ; Sill, MW; Tewari, KS | 1 |
| Eskander, RN; Tewari, KS | 1 |
| Barnett, JC; Havrilesky, LJ; Leath, CA; Phippen, NT | 1 |
| Bender, DP; Carter, JS; Dawson, D; Deng, W; Gray, HJ; Guaglianone, PP; Kunos, C; Lea, JS; Moore, KN; Zanotti, KM | 1 |
| Huang, HQ; Landrum, LM; Leitao, MM; Long, HJ; Method, M; Michael, H; Monk, BJ; Oaknin, A; Penson, RT; Ramondetta, LM; Reid, TJ; Stockman, S; Tewari, KS; Wenzel, LB | 1 |
| Krill, LS; Tewari, KS | 1 |
| Chen, H; Hui, B; Liu, Z; Lu, J; Shi, F; Sun, W; Wang, J; Wang, T; Zhang, Y | 1 |
| Holman, LL; Ren, Y; Westin, SN | 1 |
| Brown, J; Landrum, LM; Leitao, MM; Long, HJ; Michael, HE; Monk, BJ; Moore, DH; Penson, RT; Poveda, A; Reid, TJ; Sill, MW; Tewari, KS | 1 |
| Chen, ZJ; Xie, BB; Zhang, HY; Zhang, Z | 1 |
| Brown, J; Burzawa, JK; Byers, LA; Coleman, RL; Frumovitz, M; Munsell, MF; Ramalingam, P | 1 |
| Kamposioras, K; Papaxoinis, G; Pectasides, D; Pectasides, E | 1 |
| Brewster, WR; Burger, RA; Gatcliffe, TA; Kuo, JV; Monk, BJ; Shah, A; Tewari, KS | 1 |
| Arias, D; Candelaria, M; Cantu, D; Cetina, L; Coronel, J; Dueñas-González, A; González-Fierro, A | 1 |
| Deslandres, M; Guillemet, C; Hardy-Bessard, AC; Kurtz, JE; Largillier, R; Lavau-Denes, S; Paraiso, D; Pujade-Lauraine, E; Roemer-Becuwe, C; Weber, B | 1 |
| Griffin, D; Hunter, JE; Phillips, B; Puls, LE; Schammel, C | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW | 1 |
| Bell, J; Blessing, JA; Buekers, TE; Fiorica, JV; Hoffman, JS; Puneky, LV; Schilder, JM; Secord, AA; Yamada, SD | 1 |
| Bloss, JD; Long, HJ; Monk, BJ; Moore, DH; Omura, GA; Tian, C | 1 |
| Monk, BJ; Tewari, KS | 1 |
| Eastwood, A; Manca, A; Misso, K; Palmer, S; Paton, F; Paulden, M; Saramago, P | 1 |
| Bae, DS; Choi, CH; Kim, BG; Kim, MK; Kim, TJ; Lee, JH; Lee, JW; Lee, YY; Park, HS; Song, TJ | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, D; Huang, HQ; McMeekin, DS; Monk, BJ; Ramondetta, L; Wenzel, L | 1 |
| Benedetti Panici, P; Carrone, A; Di Tucci, C; Esposito, F; Giorgini, M; Manci, N; Marchetti, C; Musella, A; Palaia, I; Perniola, G | 1 |
| Fusco, E; Lorusso, D; Mainenti, S; Malaguti, P; Masciullo, V; Pietragalla, A; Scambia, G | 1 |
| Cetina, L; Coronel, J; Dueñas-Gonzalez, A | 1 |
| Ahmed, A; Fracasso, PM; Fusco, N; McMeekin, DS; Rose, PG; Salani, R; Sill, MW; Wolfson, AH; Yamada, SD | 1 |
| Fabbro, M; Floquet, A; Freyer, G; Gladieff, L; Hardy-Bessard, AC; Joly, F; Kaminski, MC; Kurtz, JE; Pujade-Lauraine, E; Raban, N; Ray-Coquard, I | 1 |
| Bian, ML; Higuma, C; Isaka, K; Ito, H; Liang, J; Nishi, H; Sasaki, T | 1 |
| Babilonti, L; Cormio, G; Ditto, A; Franchi, M; Ghezzi, F; Giorda, G; Giudici, S; Grijuela, B; Lorusso, D; Lorusso, M; Raspagliesi, F; Scambia, G; Zanaboni, F | 1 |
| Blank, S; Muggia, F; Musa, F | 1 |
| Fiorica, JV | 2 |
| Bonnar, J; Gleeson, NC; McGuinness, EP; O'Toole, SA; Sheppard, BL; Yoneda, M | 1 |
| Brafman, LB; Hershman, DL; Resnik, EE; Selleck, MJ; Shriberg, L; Smith, D; Tiersten, AD; Troxel, AB | 1 |
| Cella, D; Huang, HQ; Long, HJ; Monk, BJ | 1 |
| Benda, JA; Bundy, BN; Eaton, LA; Fiorica, JV; Grendys, EC; Long, HJ; McMeekin, DS; Miller, DS; Sorosky, J | 1 |
| Eaton, LA; Fiorica, JV; Grendys, EC; Huang, HQ; Long, HJ; McMeekin, DS; Miller, DS; Monk, BJ; Sorosky, J | 1 |
| Alvarez, RD; Buchsbaum, DJ; Grizzle, WE; Oliver, PG; Straughn, JM; Wang, W; Zhou, T | 1 |
| duPont, NC; Monk, BJ | 1 |
| Abraham, S; Booth, B; Brave, M; Dagher, R; Farrell, A; Gobburu, J; Jiang, X; Justice, R; Pazdur, R; Ramchandani, R; Sridhara, R | 1 |
| Monk, BJ; Randall-Whitis, LM | 1 |
| Amant, F; Cadron, I; Leunen, K; Neven, P; Van Gorp, T; Vergote, I | 1 |
| Coleman, RL; Miller, DS | 1 |
| Andersen, WA; Blessing, JA; Bookman, MA; Hanjani, P; Herzog, TJ | 1 |
| Amo-Takyi, BK; Boabang, P; Kohlhagen, H; Kurbacher, CM; Waida, A | 1 |
| Ampil, F; Bell, MC; Davidson, SA; Mathis, JM | 1 |
| Blessing, JA; Levenback, C; Moore, JL; Muderspach, LI | 1 |
| Donato, NJ; Ling, YH; Perez-Soler, R | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Souglakos, J; Vamvakas, L; Vardakis, N | 1 |
| Boothby, R; DeCesare, S; Fiorica, J; Grendys, E; Hoffman, M; Holloway, R; LaPolla, J; Ndubisi, B; Orr, J; Patel, J | 1 |
| Avila, A; Dunton, CJ; King, SA; Neufeld, J; Perez, G; Tolosa, J; Underhill, K | 1 |
13 review(s) available for topotecan and Cancer of Cervix
| Article | Year |
|---|---|
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2017 |
Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mass Screening; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Topotecan; Uterine Cervical Neoplasms | 2014 |
Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2015 |
Chemotherapy for recurrent cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms | 2008 |
Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cost-Benefit Analysis; Cross-Linking Reagents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Quality of Life; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Topotecan; Treatment Outcome; United Kingdom; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2010 |
Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2011 |
A pharmacokinetic evaluation of topotecan as a cervical cancer therapy.
Topics: Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Female; Humans; Topoisomerase I Inhibitors; Topotecan; Uterine Cervical Neoplasms | 2013 |
Update on the treatment of cervical and uterine carcinoma: focus on topotecan.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Endometrial Neoplasms; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Salvage Therapy; Topotecan; Uterine Cervical Neoplasms | 2002 |
The role of topotecan in the treatment of advanced cervical cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Drug Synergism; Etoposide; Female; Humans; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2003 |
Chemotherapy in the management of cervical carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Neoplasm Recurrence, Local; Palliative Care; Topotecan; Uterine Cervical Neoplasms | 2006 |
Topotecan in the management of cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Topotecan; Uterine Cervical Neoplasms | 2007 |
Chemotherapy for recurrent cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Topotecan; Uterine Cervical Neoplasms | 2007 |
Topotecan in the treatment of gynecologic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Genital Neoplasms, Female; Humans; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Uterine Cervical Neoplasms | 1997 |
30 trial(s) available for topotecan and Cancer of Cervix
| Article | Year |
|---|---|
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Quality of Life; Topotecan; Uterine Cervical Neoplasms; Withholding Treatment | 2020 |
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Topotecan; Uterine Cervical Neoplasms; Young Adult | 2013 |
Improved survival with bevacizumab in advanced cervical cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Analysis; Topotecan; Uterine Cervical Neoplasms | 2014 |
A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma; Cell Cycle Proteins; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Polyethylene Glycols; Recombinant Proteins; Ribonucleotide Reductases; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms | 2015 |
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Quality of Life; Risk Factors; Surveys and Questionnaires; Time Factors; Topotecan; Treatment Outcome; United States; Uterine Cervical Neoplasms | 2015 |
Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; Middle Aged; Risk; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms | 2015 |
Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Kaplan-Meier Estimate; Neoplasm Staging; Odds Ratio; Paclitaxel; Prognosis; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms | 2015 |
A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Staging; Survival Rate; Topotecan; Uterine Cervical Neoplasms | 2009 |
Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Topotecan; Uterine Cervical Neoplasms | 2009 |
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Drug Synergism; Female; Humans; Middle Aged; Topotecan; Uterine Cervical Neoplasms | 2009 |
A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan; Uterine Cervical Neoplasms | 2010 |
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult | 2009 |
A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Middle Aged; Topotecan; Uterine Cervical Neoplasms | 2009 |
Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2010 |
A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Topotecan; Uterine Cervical Neoplasms | 2011 |
Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Topoisomerase I Inhibitors; Topotecan; Treatment Failure; Uterine Cervical Neoplasms | 2011 |
A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Topotecan; Uterine Cervical Neoplasms | 2012 |
Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Recurrence; Topotecan; Uterine Cervical Neoplasms | 2012 |
Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2013 |
Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2004 |
Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Middle Aged; Prognosis; Prospective Studies; Quality of Life; Topotecan; Uterine Cervical Neoplasms | 2005 |
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doxorubicin; Female; Humans; Methotrexate; Middle Aged; Quality of Life; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Vinblastine | 2005 |
Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration Schedule; Female; Humans; Methotrexate; Quality of Life; Topotecan; Uterine Cervical Neoplasms; Vinblastine | 2006 |
Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Topotecan; Uterine Cervical Neoplasms | 2006 |
Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Topotecan; Uterine Cervical Neoplasms | 2000 |
Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Topotecan; Uterine Cervical Neoplasms | 2001 |
A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Topotecan; Uterine Cervical Neoplasms | 2001 |
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms | 2001 |
Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Uterine Cervical Neoplasms | 2002 |
Phase I study of topotecan and radiation therapy in advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Middle Aged; Radiation-Sensitizing Agents; Topotecan; Uterine Cervical Neoplasms | 2002 |
18 other study(ies) available for topotecan and Cancer of Cervix
| Article | Year |
|---|---|
Ricolinostat suppresses proliferation, promotes apoptosis, and enhances the antiproliferative activity of topoisomerase inhibitors in cervical cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Etoposide; Female; Humans; Reactive Oxygen Species; Topoisomerase Inhibitors; Topotecan; Uterine Cervical Neoplasms | 2022 |
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cervix Uteri; Cisplatin; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Registries; Retrospective Studies; Topotecan; Uterine Cervical Neoplasms | 2023 |
Delayed vaccine-induced CD8
Topics: Animals; Cancer Vaccines; CD27 Ligand; CD8-Positive T-Lymphocytes; Cell Proliferation; Cisplatin; DNA Topoisomerases, Type I; Female; Humans; Mice; Papillomavirus E7 Proteins; Topotecan; Tumor Microenvironment; Uterine Cervical Neoplasms; Vaccines, Subunit | 2023 |
Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Female; HeLa Cells; Humans; Hydroxamic Acids; Indoles; Membrane Potential, Mitochondrial; Panobinostat; Reactive Oxygen Species; Topoisomerase Inhibitors; Topotecan; Uterine Cervical Neoplasms; Wound Healing | 2018 |
ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma; Cisplatin; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pelvic Neoplasms; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms | 2017 |
The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms | 2018 |
Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Decision Support Techniques; Female; Humans; Models, Economic; Paclitaxel; Topotecan; United States; Uterine Cervical Neoplasms | 2015 |
Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report.
Topics: Cisplatin; Female; Humans; Middle Aged; Paclitaxel; Seizures; Status Epilepticus; Topotecan; Uterine Cervical Neoplasms | 2015 |
Development and evaluation of topotecan loaded solid lipid nanoparticles: A study in cervical cancer cell lines.
Topics: Cell Line, Tumor; Female; Humans; Lipids; Microscopy, Electron, Scanning; Nanoparticles; Topoisomerase I Inhibitors; Topotecan; Uterine Cervical Neoplasms | 2016 |
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Young Adult | 2017 |
Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Disease-Free Survival; Female; Humans; Ifosfamide; Logistic Models; Middle Aged; Models, Statistical; Multivariate Analysis; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2010 |
The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Synergism; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Salvage Therapy; Topotecan; Uterine Cervical Neoplasms | 2010 |
Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Topotecan; Uterine Cervical Neoplasms | 2010 |
The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Paclitaxel; Promoter Regions, Genetic; Reference Values; RNA, Small Interfering; Topoisomerase I Inhibitors; Topoisomerase Inhibitors; Topotecan; Ubiquitin-Conjugating Enzymes; Uterine Cervical Neoplasms | 2012 |
The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours.
Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Endometrial Neoplasms; Female; Fluorouracil; Genital Neoplasms, Female; Humans; Neoplasm Staging; Paclitaxel; Retrospective Studies; Tetrazolium Salts; Topotecan; Toxicity Tests; Treatment Outcome; Uterine Cervical Neoplasms | 2003 |
Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Combined Modality Therapy; Drug Synergism; Female; Humans; Mice; Mice, Nude; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Topotecan; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2006 |
Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Female; Humans; Luminescent Measurements; Paclitaxel; Topotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vulvar Neoplasms | 2000 |
Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Division; Cisplatin; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2001 |